Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review

Abstract Objectives To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). Data This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. Sources A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. Study selection Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21–68 weeks and 4–9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes. Conclusions Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.

Authors

Institutions

Publication Details

Journal
BMC Oral Health
Published
2026-11-14
DOI
https://doi.org/10.1186/s12903-026-10305-6
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review

Manuela da Silva Spinola, Matthias Hannig, João Víctor Frazão Câmara, Anton Schestakow et al.
BMC Oral Health
Diabetes Treatment and Management
article

Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review

Manuela da Silva Spinola, Matthias Hannig, João Víctor Frazão Câmara, Anton Schestakow, Débora Heller, Daniella Muknickas
article en

Abstract

Abstract Objectives To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). Data This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. Sources A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. Study selection Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21–68 weeks and 4–9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes. Conclusions Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.

BMC Oral HealthVol. 26(1)
University of Tennessee Health Science Center (US), The University of Texas at San Antonio Health Science Center (US), Saarland University (DE)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon